Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)

The durability of a three-dose extended primary series of COVID-19 vaccine in dialysis patients remains unknown. Here, we assessed dynamic changes in SARS-CoV-2-specific humoral and cell-mediated immunity at baseline, 3 months, and 6 months after the extended primary series in 29 hemodialyzed (HD),...

Full description

Bibliographic Details
Main Authors: Sarinya Boongird, Chavachol Setthaudom, Rungthiwa Kitpermkiat, Somsak Prasongtanakij, Supanart Srisala, Piyatida Chuengsaman, Arkom Nongnuch, Montira Assanatham, Sasisopin Kiertiburanakul, Kumthorn Malathum, Angsana Phuphuakrat, Jackrapong Bruminhent
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
COVID-19 vaccine
dialysis
immune response
inactivated SARS-CoV-2 vaccine
neutralizing antibody
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/10/7/1064

Internet

https://www.mdpi.com/2076-393X/10/7/1064

Similar Items